Twitter Beğeni Hilesi

Maintenance oral etoposide after high-dose chemotherapy (HDCT) for patients with relapsed metastatic germ-cell tumors. #BeyondTheAbstract with Nabil Adra IU Simon Comprehensive Cancer Center. #ReadNow on UroToday > bit.ly/3zZ8Fu3 #TesticularCancer Fadi Taza Dr. Rafat Abonour MD Mohammad Abu Zaid

Teratoma in the primary tumor site was associated with a higher incidence of teratoma in residual nonretroperitoneal (non–RP) disease post-chemotherapy, according to findings from a retrospective study. Jennifer King IU School of Medicine #OncClub #tscsm ow.ly/1Y7V50OYxmG

Join us this Saturday July 15 for the 30th Anniversary of the IU Review & Interpretation of the ASCO Meeting. We have a great speaker lineup and special features! iu.cloud-cme.com/course/courseo… Tarah Ballinger, MD Jennifer King Anita Turk Greg Durm IU Simon Comprehensive Cancer Center IU School of Medicine Department of Medicine

Kudos to Nabil Adra for leading and organizing IU Simon Comprehensive Cancer Center 30th anniversary ASCO review 🙌🏼

IU Simon Comprehensive Cancer Center Jennifer King

Teratoma in the primary tumor or in post-chemotherapy residual non-retroperitoneal disease is not associated with inferior survival in metastatic non-seminomatous germ cell tumors. ja.ma/3FQe4GP

We are very excited to welcome our new class of fellows matched Indiana University Hematology/Oncology Fellowship Congratulations! We are THRILLED to have you join us and looking forward to welcoming all of you! IU Simon Comprehensive Cancer Center

GU post doc Rebecca Hassoun from IU Simon Comprehensive Cancer Center presenting real world data for predictors of PSA response to PSMA Lu-177 in metastatic castration resistant prostate cancer. IU School of Medicine Department of Medicine Jennifer King Tareq Salous #GU24

We have more work to share at @asco -GU. Tomorrow, 1/27 8-10am join us at TIP Poster Session C: TPS492 Poster Board M13. Study led by Michael B. Atkins, MD of Georgetown Lombardi meetings.asco.org/abstracts-pres… Karie Runcie, MD

IU Simon Comprehensive Cancer Center GU oncology group at #GU24 Proud to be part of this great team! Jennifer King Tareq Salous Clint Cary, MD MPH MBA Rebecca Hassoun IU School of Medicine Department of Medicine Indiana University Hematology/Oncology Fellowship Indiana University Department of Urology

Our superstar Indiana University Hematology/Oncology Fellowship fellow Ahmed Bilal Khalid and his work on BMI and outcomes in GCT patient treated with HDCT 👏 IU Simon Comprehensive Cancer Center Nabil Adra #GU24

Safety of pegfilgastrim in patients with germ cell tumors treated with bleomycin-containing regimens. No increased risk of lung toxicity! IU Simon Comprehensive Cancer Center Jennifer King IU School of Medicine Department of Medicine Rebecca Hassoun

🧬 ctDNA making progress to evaluate cancer recurrence for Stage II and Stage III non seminoma germ cell tumors #GU24 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Nabil Adra IU Simon Comprehensive Cancer Center Jennifer King Clint Cary, MD MPH MBA Rebecca Hassoun Tareq Salous

Rebecca Hassoun presenting initial results for ctDNA monitoring in patients with stage II/III non-seminomatous GCT. Need to validate data in future cohorts IU Simon Comprehensive Cancer Center #GU24 IU School of Medicine Department of Medicine Jennifer King Tareq Salous Clint Cary, MD MPH MBA Indiana University Department of Urology Dr. John Sfakianos

Pegfilgrastim in metastatic germ-cell tumor treatment with bleomycin shows no increased risk for lung toxicity. Indiana University ASCO #GU24 OncoAlert UroToday.com Toni Choueiri, MD Emre Yekedüz Amanda Nizam, MD Tian Zhang, MD, MHS Cristiane D Bergerot 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Daniel Castellano Fabio Schutz Oncology Brothers

Milwaukee is cold and it was snowing this morning 🥶😳, but still thrilled to attend my first #cgea conference. Grateful for support and mentorship IU Simon Comprehensive Cancer Center from Jennifer Schwartz MD FASCO for guiding and encouraging #meded passion

Our amazing 1st yr fellow Ahmed Bilal Khalid presenting pts with stage 1 NSGCT on active surveillance w/ RP only relapse treated with chemo vs RPLND. Important features of pts carefully selected for RPLND: ☑️Normal tumor markers ☑️RP LNs <3cm ☑️ Longer duration prior to relapse

Patients with relapsed germ cell tumors with progressive brain metastases are curable with multimodal therapy which includes high-dose chemotherapy + SCT. Aggressive and efficient management of these patients can alter outcomes. Jennifer King IU Simon Comprehensive Cancer Center Indiana University Hematology/Oncology Fellowship #ASCO24

🚀 Brilliant poster presentation by Rebecca Hassoun on longitudinal evaluation of ctNA as a prognostic biomarker to detect minimal residual disease in testicular cancer #ASCO24 ‼️ ASCO ASCO TECAG OncoAlert

In 1974, the survival rate for testicular cancer was just 5%. Today, thanks to the groundbreaking work of Lawrence Einhorn, MD, at IU Simon Comprehensive Cancer Center, that number has soared to more than 95%. Join us in celebrating 50 years of transformative research: ow.ly/Fvto50Tpzw6.